Chronic, recurrent Lymphocytic Leukemia Not Yet Recruiting Phase 2 Trials for Obinutuzumab (DB08935)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04169737Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTreatment